|
US6911447B2
(en)
|
2001-04-25 |
2005-06-28 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
|
US7115607B2
(en)
|
2001-07-25 |
2006-10-03 |
Amgen Inc. |
Substituted piperazinyl amides and methods of use
|
|
US7354923B2
(en)
|
2001-08-10 |
2008-04-08 |
Palatin Technologies, Inc. |
Piperazine melanocortin-specific compounds
|
|
US7655658B2
(en)
|
2001-08-10 |
2010-02-02 |
Palatin Technologies, Inc. |
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
|
|
US7718802B2
(en)
|
2001-08-10 |
2010-05-18 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
|
US7732451B2
(en)
|
2001-08-10 |
2010-06-08 |
Palatin Technologies, Inc. |
Naphthalene-containing melanocortin receptor-specific small molecule
|
|
US7456184B2
(en)
|
2003-05-01 |
2008-11-25 |
Palatin Technologies Inc. |
Melanocortin receptor-specific compounds
|
|
AU2002331064B2
(en)
|
2001-08-10 |
2007-08-23 |
Palatin Technologies, Inc. |
Peptidomimetics of biologically active metallopeptides
|
|
WO2003061660A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Eli Lilly And Company |
Melanocortin receptor agonists
|
|
US7026335B2
(en)
|
2002-04-30 |
2006-04-11 |
The Procter & Gamble Co. |
Melanocortin receptor ligands
|
|
WO2004024720A1
(en)
|
2002-09-11 |
2004-03-25 |
Merck & Co., Inc. |
Piperazine urea derivatives as melanocortin-4 receptor agonists
|
|
TW200504033A
(en)
*
|
2002-10-23 |
2005-02-01 |
Procter & Gamble |
Melanocortin receptor ligands
|
|
WO2004081643A1
(en)
*
|
2002-12-20 |
2004-09-23 |
Kaiser Aerospace & Electronics Corp. |
Lenslet array with polarization conversion
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
US20060178403A1
(en)
*
|
2003-03-07 |
2006-08-10 |
Neurocrine Biosciences, Inc. |
Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
|
|
US7968548B2
(en)
|
2003-05-01 |
2011-06-28 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine compounds with diamine groups
|
|
US7727990B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine and keto-piperazine compounds
|
|
US7727991B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific single acyl piperazine compounds
|
|
GB0324236D0
(en)
*
|
2003-10-16 |
2003-11-19 |
Astrazeneca Ab |
Chemical compounds
|
|
US20050119252A1
(en)
*
|
2003-10-22 |
2005-06-02 |
Neurocrine Biosciences, Inc. |
Ligands of melanocortin receptors and compositions and methods related thereto
|
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
|
|
US7709484B1
(en)
|
2004-04-19 |
2010-05-04 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
|
CN101094689B
(zh)
|
2004-11-01 |
2013-06-12 |
安米林药品有限责任公司 |
治疗肥胖以及肥胖相关疾病和病症的方法
|
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
|
EP1831194A4
(en)
*
|
2004-12-21 |
2009-12-02 |
Astrazeneca Ab |
HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
|
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US20070021433A1
(en)
|
2005-06-03 |
2007-01-25 |
Jian-Qiang Fan |
Pharmacological chaperones for treating obesity
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
US7834017B2
(en)
|
2006-08-11 |
2010-11-16 |
Palatin Technologies, Inc. |
Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
|
|
US20080108574A1
(en)
*
|
2006-09-27 |
2008-05-08 |
Braincells, Inc. |
Melanocortin receptor mediated modulation of neurogenesis
|
|
GB0624987D0
(en)
|
2006-12-14 |
2007-01-24 |
Acure Pharma Ab |
Novel aminoguanidines as melanocortin receptor ligands
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
EP2072050A1
(en)
|
2007-12-21 |
2009-06-24 |
Santhera Pharmaceuticals (Schweiz) AG |
Compounds with anti-emetic effect
|
|
WO2009120836A1
(en)
|
2008-03-26 |
2009-10-01 |
Neurosigma, Inc. |
Methods for identifying and targeting autonomic brain regions
|
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
FR2937973B1
(fr)
*
|
2008-11-04 |
2010-11-05 |
Galderma Res & Dev |
Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
|
FR2937868B1
(fr)
*
|
2008-11-04 |
2010-11-05 |
Galderma Res & Dev |
Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
|
EP2358200A4
(en)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
|
|
CA2768577A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
WO2011137024A1
(en)
|
2010-04-26 |
2011-11-03 |
Merck Sharp & Dohme Corp. |
Novel spiropiperidine prolylcarboxypeptidase inhibitors
|
|
EP2568812B1
(en)
|
2010-05-11 |
2016-10-26 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
|
WO2011153359A1
(en)
|
2010-06-04 |
2011-12-08 |
Albany Molecular Research, Inc. |
Glycine transporter-1 inhibitors, methods of making them, and uses thereof
|
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012100342A1
(en)
|
2011-01-27 |
2012-08-02 |
Université de Montréal |
Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
|
KR20150118158A
(ko)
|
2013-02-22 |
2015-10-21 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병 비시클릭 화합물
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298B1
(en)
|
2016-12-20 |
2026-03-11 |
Merck Sharp & Dohme LLC |
Antidiabetic spirochroman compounds
|
|
AU2019280689B2
(en)
|
2018-06-05 |
2024-09-05 |
Crinetics Pharmaceuticals, Inc. |
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
|
|
US12479825B2
(en)
|
2019-11-07 |
2025-11-25 |
Crinetics Pharmaceuticals, Inc. |
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
|
|
CA3164117A1
(en)
|
2019-12-18 |
2021-06-24 |
Crinetics Pharmaceuticals, Inc. |
Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
ES3032933T3
(en)
|
2019-12-23 |
2025-07-29 |
Crinetics Pharmaceuticals Inc |
Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
AU2022240609A1
(en)
|
2021-03-19 |
2023-09-28 |
Crinetics Pharmaceuticals, Inc. |
Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
|
|
CN113527220A
(zh)
*
|
2021-07-26 |
2021-10-22 |
京博农化科技有限公司 |
一种脱硫丙硫菌唑异构体的合成方法
|